Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs TransMedics Group Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $80.9 (market cap $2.06B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 36 Days and TransMedics Group Inc for 24 Days on average.
| ROBO | TMDX | |
|---|---|---|
Market Cap | $2.06B | $2.74B |
Volume | 148,111 | 949,331 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $150.42 |
52-Week Low | $63.04 | $61.99 |
Typical Hold Time | 36 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $81.82, down 1.89% today amid mixed technical signals. The overall technical outlook remains bullish with strong moving average support, though oscillators show bearish momentum with RSI levels above 79 indicating potential overbought conditions. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with Q2 2026 earnings showing broadening demand for physical AI technologies.
The robotics ETF offers diversified exposure to a sector benefiting from labor shortages and AI infrastructure growth. Key risks include valuation concerns amid rapid sector expansion and potential market volatility. Analyst coverage remains positive on long-term robotics adoption trends, though current technical indicators suggest near-term consolidation may be needed after recent gains.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
